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travenous histamine (a vasopressorl. Thrombi were present in 19 of 34 aor-
tic plaques but none of 11 aortic sections from the normal rabbits. The 34
plaques and 11 normal sections were stained with antibody to tissue factor.
While none of the normal specimens had luminal surface tissue factor, it was
found on the surface of 17/19 (87%) of plaques with thrombi and 7/15 (45%)
of plaques without thrombi (p = 0.009).
r- p<O.001 -I
I r- p<0.01--,
I 17119
Conclusion: Plaques associated with thrombi were significantly more likely
to have luminal tissue factor than those without thrombi. These findings sup-
port the importance of tissue factor as a link between atherosclerosis and
thrombosis.
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Restoration of Thromboresistance in Injured Aortic
Segments by a Novel Nitric Oxide Donor
Tasneem Z. Naqvi, Michael C. Fishbein, Bojan Cercek, Arun M. Thomas, Mia
D. Molloy, Lina Badimon, Prediman K. Shah. Thomas C. Hutsell. Sanjay Kaul.
Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA: Comedicus
Incorporated, Minneapolis, MN
Endothelium-derived nitric oxide (NO) is one of the principal mediators of
thromboresistance in intact blood vessels. To determine whether repletion
of NO would restore thromboresistance in injured arterial segments, we in-
vestigated the effect of a novel short-lived NO donor - NO adduct of N,N'-
dimethylhexanediamine (DMHD/NO) on arterial injury-induced thrombosis
in an ex vivo rabbit carotid-jugular arteriovenous shunt model. Segments
of porcine aortic subendothelium (endothelium-deficient but intact internal
elastic lamina) and media, simulating mild and deep arterial injury, respec-
tively, were placed in a Badimon perfusion chamber and exposed to flowing
arterial blood from hypercholesterolemic (He) rabbits (cholesterol of 431 ±
187 mg/dL. n = 5) for 10 minutes at a shear rate of 1700/s (typical of mild
coronary stenosis). Thrombus volume was quantified in control and treated
segments by morphometry of histological sections. Treatment consisted of
DMHD/NO 10.01 /tM) and phosphate buffered saline as control. Thrombus
formation was minimal in subendothelium (8 ± 4/tm3//tm 2 of exposed area),
whereas media developed large thrombi (78 ± 15 /tm3//tm 2 (p = O.OOli.
DMHD/NO strikingly reduced thrombus volume in media by 85 ± 5% to 15
± 6 /tm3//tm 2, thereby effectively reversing thrombus formation to that in
subendothelium. Infusion of saline had no effect on thrombus formation.
Mean arterial pressure fell by about 3% after infusion of DMHD/NO.
Conclusion: In this ex vivo model of arterial thrombosis 1) deeply injured-
arterial segments (media) were highly thrombogenic and mildly injured-
arterial segments Isubendotheliuml were relatively thromboresistant. and 2)
DM HD/NO, a novel nitric oxide donor, effectively restored thromboresistance
in deeply injured-arterial segments without producing significant systemic
hemodynamic effects.
The presence of residual mural thrombus (MT) predisposes to recurrent
thrombotic vessel occlusion. To compare the benefits of different antithrom-
botic and anti platelet agents we studied the growth of thrombus on a pre-
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Comparative Effects of Heparin, Aspirin, and Hirudin
on Thrombus Growth on Fresh Mural Thrombus:
Deaggregation of Mural Thrombus by Specific
Thrombin Inhibition
Beat J. Meyer 1, Juan J. Badimon, John 1. Fallon, Valentin Fuster, James
H. Chesebro, Lina Badimon 1University Hospital Bern, Switzerland: Mount Sinai
Medical Center. New York
N Acute Restenosis Repeat PTA Long-term
Success Stent. Surgery Success
Group I 26 80% 82% 76% 30%
Group II 13 100% 23% 23% 84%
p-vaJue 0.17 <0.001 <0.008 <0.005
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Differential Expression of Tissue Factor Protein in
Directional Atherectomy Specimens from Patients
with Stable and Unstable Coronary Syndromes
Brian H. Annex, Stephen M. Denning, Keith Channon, Michael H. Sketch, Jr.,
Richard S. Stack, Kevin G. Peters Duke University Medical Center. Durham, NC
Tissue factor (TF) is a cell membrane-associated protein that catalyzes the
rate-limiting step of the exttinsic coagulation pathway, which is the major
source of thrombin production in-vivo. To examine the potential role that
TF may play in the pathogenesis of different coronary syndromes, we stud-
ied directional coronary atherectomy specimens ftom 57 patients, using im-
munohistochemical techniques. Patients were classified according to their
admission diagnosis as having either an unstable coronary syndrome, which
required the presence of rest angina or post-infarction 1<1 week) angina,
or stable coronary syndromes which included stable, progressive and new-
onset angina without rest chest pain. Lesions were also classified as a de-
novo or a restenosis lesion. Frozen sections were examined for the presence
of TF using a murine IgG monoclonal antibody against human tissue fac-
tor. Samples were read independently by two investigators without knowl-
edge of the clinical information. The results were expressed dichotomously
as positive or negative using human skin sections as a positive control and
a nonsense murine monoclonal antibody as a negative control. Statistical
analysis were performed using a Chi-Square or Fischer's Exact Test. For the
entire study group, TF was detected in 15 (45%) of 33 patients with unstable
coronary syndromes versus only 3 (13%1 of 24 patients with stable coronary
syndromes; p :s 0.02. Moreover, within the subgroup of patients with unsta-
ble coronary syndromes, TF protein was detected in 14 (61 %) of 23 patients
with de-novo lesions versus only 1 (10%) of 10 patients with rest angina from
a restenosis lesion; p :s 0.01. An additional 7 patients with stable coronary
syndromes due to a restenosis lesion were also all negative for TF, for an
overall incidence of only 1 (6%1 of 17 restenosis lesions.
In conclusion, tissue factor is readily detected in atherectomy specimens
from de-novo lesions in patients with unstable coronary syndromes, sug-
gesting a role for this protein in the pathogenesis of this disease process.
Conversely, tissue factor is rarely detected in patients with restenosis lesions
even if the clinical presentation is an unstable coronary syndrome. These re-
sults may have implications in regard to the management of patients with
unstable angina from de-novo lesions and all patients with recurrent symp-
toms from restenosis lesions.
In a subset of pts with restenosis after PTA, repeat balloon angioplasty (N
= 14) resulted in a 100% restenosis; however, central vein stenting (N = 8)
was associated with recurrent restenosis in only 38% (p < 0.0005).
Conclusion: PTA of central venous occlusions in dialysis patients is asso-
ciated with a very high restenosis rate, especially in patients with prior an-
gioplasty. Because stenting has an excellent acute success rate and lower
restenosis rate, it appears to be a better treatment option in these patients.
Atherosclerotic plaque disruption and thrombosis are now recognized as ma-
jor causes of acute coronary syndromes. Tissue factor may playa central role
in linking plaque disruption to thrombus formation. We utilized an atheroscle-
rotic rabbit model of plaque disruption and thrombosis to determine the re-
lationship between luminal surface tissue factor and arterial thrombi.
Triggering was attempted in 11 atherosclerotic rabbits and 5 normal rab-
bits using only intraperitoneal Russell viper venom (a procoagulant) and in-
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Increased Tissue Factor at Sites of Thrombosis in an
Atherosclerotic Animal Model
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existing mural thrombus in a well characterized porcine perfusion system in
which a fresh mural thrombus was formed by perfusing severely injured ar-
terial wall with porcine blood for 5 min at a shear rate of 1690ls (correspond-
ing to a moderate coronary stenosis). Thrombus formation was measured
by morphometric analysis. The average mural thrombus achieved in 5 min
was 0.135 mm21mm (n ~ 17).
To quantify the growth of thrombus, MT was perfused with whole blood
of control and treated animals at the same flow conditions.
Thrombus growth on MT was evaluated in pigs treated with Placebo, As-
pirin (ASA, 5 mglkg iv). Heparin IHep, 100 IU/kglh) plus ASA iv, high-dose
Hep (250 IUlkglh ivl, and r-Hirudin (1 mg/kglh ivl as a probe for thrombin. An-
ticoagulation was evaluated by aPIT (sec). Results expressed as thrombus
area (TA mm2lmm, ± SEM) and % growth of thrombus (GT) on MT were
compared by Anova:
Placebo ASA Hep + ASA Hep 250 r-Hir
28 13 6 14 13
TA 0.29 ± 0.01 0.28 ± 0.02 0.20 ± 0.02* 0.15 ± 001* 007 ± 0.01*#1
%GT +119 ± 14 +110± 11 +48 ± 12* +13 ± 5* -48 ± 2*#1
apn 31 ± 3 32 ± 5 46 ± 2 >300 68 ± 3
p < 0.05: * vs Placebo; # vs hep250, 1 vs MT
after initial thrombolysis. We hypothesized that administration of Iys-
plasminogen, which binds to fibrinogen with 10 times greater affinity and
results in a loose fibrin structure (vs native glu-plasminogen) may enhance
the thrombolytic efficacy of t-PA. To examine this hypothesis, dogs with
electrically-induced stable thrombus in the LAD coronary artery were treated
with saline (n = 10) or Iys-plasminogen (2 mg/kg, n = 5) followed 10 minutes
later byt-PA(l mglkg over20 min). Five other dogs with occlusive LAD throm-
bus were first given t-PA followed by Iys-plasminogen (2 mglkg) 40 minutes
later. Blood flow characteristics were observed for 2 hours. Lys-plasminogen
given before t-PA restored flow in all dogs (vs 75% in saline + t-PA group)
in 14 ± 4 minutes (vs 24 ± 3 minutes, P < 0.05) lasting <2 hours (vs 41
± 5 minutes, P < 0.02) with coronary reocclusion rate of 0% (vs 71 %, P
< 0.02). In dogs given Iys-plasminogen after t-PA. the reperfusion rate was
75%, time to reflow 32 ± 6 min, duration of flow 25 ± 19 min and the reoc-
clusion rate 75% (P < 0.05 vs dogs given Iys-plasminogen before t-PA; P-NS
vs dogs given saline + t-PA). Thus recombinant Iys-plasminogen given be-
fore t-PA markedly decreases time to thrombolysis and results in sustained
thrombolysis. In contrast, Iys-plasminogen given after t-PA has no effect on
these parameters of thrombolysis. Enhanced binding of Iys-plasminogen to
fibrinogen in the thrombus resulting in easily dissolvable clot structure may
be the basis of these observations.
These data suggest that by directly inhibiting thrombin activity, r-hirudin
completely inhibits growth of thrombus and is more effective al lower lev-
els of anticoagulation than the highest does of heparin. Specific thrombin
inhibition also leads to an overall reduction of the mural thrombus at shear
rates typical of a moderate coronary stenosis indicating deaggregation of a
pre-existing mural thrombus.
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In conclusion, Ad causes marked shortening of human atrial action poten-
tial at doses even lower than those used clinically. These effects are rate-
dependent and may account for induction of atrial fibrillation by Ad.
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Administration of adenosine (Ad) frequently terminates reentrant supraven-
tricular tachycardias and may precipitate atrial fibrillation. We characterized
the electrophysiologic effects of incremental doses (1,3,6 mg) of Ad in 8 pts
(age 24-60) during elective electrophysiologic study. Ad was administered
via a central catheter during pacing at cycle lengths (CU of 800, 600 and 500
msec. Monophasic action potentials (MAP) were simultaneously recorded
from the RA and RV and analyzed off-line. Results: Ad decreased atrial MAP
at 90% repolarization (CL 600 msec) by 14, 28 and 35% (1, 3, 6 mg respec-
tively). Ad's atrial effects were rate-dependent (graph A) and dissipated with
a mean time constant of 3.2 ± 0.58 msec (graph BI.
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1798-1 I Electrophysiologiesl Effects of Adenosine on Human
Monophasic Action Potentials
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1798-21 Differential Sensitivity of AV and VA Conduction to
Adenosine In Humans
Wen-Ter Lai, Sheng-Nan Wu, Chee-Siong Lee, Jung-Chou Wu, Sheng-Shiung Sheu,
Yeo-Shin Hwang, Luiz Belardinelli. Kaohsiung Medical College, Kaohsiung, Taiwan;
University of Florida, Gainesville, Florida
Studies in rat isolated hearts suggest that adenosine is more potent for slow-
ing antegrade atrioventricular (AV) than retrograde ventriculo-atrial (VA) con-
duction. The potency (EC50) and maximal effect (Emax ) of adenosine to slow
AV and VA conductions were determined in 16 patients (mean age 48 years).
These patients were selected from a group that had a common form of AV
nodal reentrant tachycardia who had prior to the study been subjected to
selective radiofrequency ablation of the slow pathway conduction, but with
intact antegrade and retrograde fast pathway conduction. During high right
atrial and ventricular pacing at comparable cycle lengths (400-500 msec).
adenosine was injected as an intravenous bolus at an initial dose of 0.5 mg
followed by stepwise increase of 1 mg given every 5 minutes until AV or
VA block occurred. The dose-response curves for adenosine-induced pro-
Age (Vr) SMCs MACs T-cells PMNs NC CAL
PR, n = 24 52 ± 10 8% 67% 100% 8% 83% 71%
SU,n = 18 44 ± 7 61% 22% 36% 28% 33% 28%
p-value <0.02 <0.001 <0.01 <0.005 0.12 <0.01 <0.02
SMCs (= smooth muscle cells), MACs I~ macrophages), T-cells, and PMNs (~ neu-
trophils) in plaque adjacent to thrombus: NC = large necrotic core; CAL = calcified plaque
The luminal surface of SU plaques contained accumulations of SMCs
within a proteoglycan matrix. In PR cases, the ruptured fibrous cap was typ-
ically infiltrated by MACs and T-cells. Expression of HLA-DR antigens was
present in MACs and T-cells in 62% of PR cases and expressed in SMCs in
14% of SU cases (p < 0.02). The percent luminal area stenosis was 79 ± 13%
in PR and 71 ± 14% in SU, p < 0.05. No differences in plaque eccentricity
or occlusive vs. non-occlusive thrombi were noted. Conclusions: Superficial
ulceration of smooth muscle cell-rich plaques lacking plaque rupture into a
large necrotic core is a frequent (43%) finding in coronary thrombosis and
is more often seen in younger persons with non-calcified plaques and less
luminal narrowing. The mechanism of coronary artery thrombosis in plaques
rich in SMCs is not mediated by HLA-DR expression and warrants further
study.
Tissue-plasminogen activator (t-PA) activates plasminogen to plasmin which
results in clot lysis. While t-PA administration rapidly restores blood flow
in the thrombosed coronary artery, the coronary artery often reoccludes
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1797-51 Ulceration of Smooth Muscle Cell-Rich Plaques: A
Frequent Cause of Coronary Artery Thrombosis That
is not Mediated by HLA-DR Expression
Andrew Farb, Anita L. Tang, Allen P. Burke, Youhai Liang, Poonam Mannan,
John Smialek, Renu Virmani Armed Forces Institute of Pathology, Washington, DC
Coronary artery thrombosis (CAT) is reported to occur primarily from plaque
rupture (PRI involving disruption of a fibrous cap over a necrotic core. How-
ever, CAT associated with superficial ulceration ISUI of predominately fi-
bromuscular plaques without rupture of a necrotic core is under-reported.
We performed post-mortem angiography, detailed coronary histology, mor-
phometry, and immunohistochemistry in 42 cases (33 men, 9 women) of
sudden death due to CAT. All individuals died :06 hours of symptom onset.
Histo- and immunochemical stains consisted of Movat pentachrome, H&E,
smooth muscle specific actin, KP-1 (for macrophages). UCHL1 (for T-cells),
Leder stain Ifor neutrophils). and HLA-DR. Results:
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1797-61 Recombinant Lys-Plasminogen Given Prior to, but
not After, Tissue-Plasminogen Activator Markedly
Improves Coronary Thrombolysis in Dogs
Living Chen, Wilmer W. Nichols, Tom G.P. Saldeen, Jawahar L. Mehta. University of
Florida, Gainesville, FL; VAMG. Gainesville, FL
